Decoding oncogenic secrets of regulator of chromosome condensation 1: A breakthrough mechanistic evidence from breast and lung cancer models

PLoS ONE, Journal Year: 2025, Volume and Issue: 20(3), P. e0319748 - e0319748

Published: March 31, 2025

The Regulator of Chromosome Condensation 1 (RCC1), a master regulator cell cycle progression, chromatin structure, and nuclear transport, emerges as powerful driver cancer progression. Elevated RCC1 expression in breast lung cancers is closely tied to enhanced tumor survival, proliferation, metastasis, positioning it promising therapeutic target. This study unveils RCC1’s pivotal role biology by silencing its MDA-MB-231 (breast cancer) A549 (lung lines using shRNA. knockdown dramatically reduced viability, colony formation, motility, while inducing apoptosis, evidenced increased apoptotic markers anti-apoptotic Bcl2 expression. Gene analysis revealed downregulation DNA repair pathways, highlighting critical sustaining oncogenic mechanisms. These findings underscore gatekeeper capable resisting apoptosis promoting metastasis. Targeting offers dual advantage: disrupting growth enhancing creating an exciting opportunity for precision therapies. By illuminating integration into survival networks, this not only advances our understanding but also lays the groundwork innovative treatments aimed at halting progression

Language: Английский

---

RNA methyltransferase METTL16: from molecular mechanisms to therapeutic prospects in cancers

Cancer Letters, Journal Year: 2025, Volume and Issue: unknown, P. 217698 - 217698

Published: April 1, 2025

Language: Английский

---

An Unusual Case of Radiation-Induced Dermatofibrosarcoma Protuberans: A Rare Type of Soft Tissue Sarcoma

International Journal of Cancer Management, Journal Year: 2025, Volume and Issue: 18(1)

Published: May 4, 2025

Introduction: Dermatofibrosarcoma protuberans (DFSP) is a rare, locally aggressive soft tissue sarcoma characterized by low metastatic potential but high local recurrence rate. It typically managed with wide surgical excision, adjuvant therapies considered in cases of inadequate margins or high-grade variants. Ionizing radiation known to induce various malignant skin tumors, radiation-induced DFSP exceptionally only few documented cases. This case report presents an unusual instance DFSP, highlighting the challenges diagnosis and management this rare complication following therapy. The underscores importance long-term surveillance patients history exposure need for early recognition secondary malignancies. Case Presentation: We reported patient breast, which was confirmed immunohistochemistry (IHC). tumor developed at radiotherapy field 6 years after underwent breast-conserving surgery breast cancer. A excision performed, since margin 3 cm negative, did not require radiotherapy. She now remains cancer-free 4 operation completed. While has proven benefits treatment cancer, it also carries undeniable side effects, including increased risk cancers such as sarcomas. Therefore, crucial carefully consider indications volume administered. Conclusions: highlights arise cancer treated Awareness possibility timely management. precise consideration when deciding regarding therapy indications, volume, method, although likelihood developing very low, zero.

Language: Английский

---

In Silico Discovery of Multi-Target Small Molecules and Efficient siRNA Design to Overcome Drug Resistance in Breast Cancer via Local Therapy

Journal of Molecular Graphics and Modelling, Journal Year: 2025, Volume and Issue: 140, P. 109086 - 109086

Published: May 20, 2025

Language: Английский

---

In Silico Discovery of Multi-Target Natural Ligands and Efficient siRNA Design for Overcoming Drug Resistance in Breast Cancer via Local Therapy

bioRxiv (Cold Spring Harbor Laboratory), Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 11, 2024

Abstract In this study, we designed an efficient siRNA for PKMYT1 gene knockdown, and evaluated the binding affinities of different natural ligands to crucial proteins involved in breast cancer. Designed showed strong affinity minimal off-target effects. Molecular docking studies identified new as antagonists with high aromatase, estrogen receptor alpha, HER2, PARP10, well agonists MT2 STING. The ligand SCHEMBL7562664 was introduced a golden due its among multiple targets lack cytotoxic mutagenic Natural small molecules research, their multi-target characteristics, provided solution overcome problem drug resistance cancer cells. Furthermore, proposed three dimensional scaffold design local therapy offers promising approach increase delivery efficacy these molecules, reduce systemic side effects, improve treatment outcomes. significant favorable pharmacokinetic properties were identified, which paves way further research targeted

Language: Английский

---